From January 1, 2024 to April 3, 2024, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 2,000,000 shares, representing 0.12% for CNY 72.2 million under the buyback announced on April 5, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.5 CNY | +0.97% | -5.91% | -38.32% |
Apr. 26 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
Apr. 25 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.32% | 3.18B | |
-2.32% | 92.59B | |
+3.68% | 41.43B | |
-11.45% | 33.49B | |
-19.14% | 14.62B | |
-8.93% | 12.77B | |
-11.34% | 11.58B | |
-43.53% | 11.35B | |
+3.75% | 8.97B | |
-6.32% | 8.3B |
- Stock Market
- Equities
- 300142 Stock
- News Walvax Biotechnology Co., Ltd.
- Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.